Current Studies

Utah Cancer Specialists actively participates in clinical research.  This is a list of the studies currently offered at Utah Cancer Specialists.  The number following each listing is the control number assigned by the National Cancer Institute.  You may search any of these numbers at https://www.clinicaltrials.gov 

If you believe one of these studies could be right for you, please consult with your physician.  For further information, please contact us at 801 281-6864 or by email at research@utahcancer.com

Studies current as of 6/13/2017:

Breast Cancer Study (3rd Line) #BRE001:
For Study Participants with HER2+ Metastatic Breast Cancer who have Received two Prior Treatments.

NCT02492711

Breast Cancer Study #BRE002:
For Study Participants with Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer.  NCT02819518

Breast Cancer Study #BRE003:
For Study Participants with Metastatic Breast Cancer who have Stable Brain Metastases and have been previously treated with Anthracycline, A Taxane, and Capecitabine. NCT02915744

Chronic Lymphocytic Leukemia Study (2nd Line) #CLL001:
For Study Participants with Chronic Lymphocytic Leukemia (CLL).   NCT02756611

Lung Cancer Studies (1st Line) #LUN001:
For Study Participants with Metastatic Squamous Non-Small Cell Lung Cancer Participants.   NCT02775435

Lung #P1-LNG001:
For Study Participants with Non-Small Cell Lung Cancer (NSCLC).   NCT02448251 

Lung #P1-LNG002:
For Study Participants with ALK Rearranged (ALK-Positive) Metastatic Non-Small Cell Lung Cancer.   NCT02186821

Lymphoma B-Cell Malignancies #P1-LYM001:
For Study Participants with Previously Treated B-Cell Malignancies.   NCT02018861

Lymphoma Cancer Studies (1st Line) #LYM002:
For Study Participants with Previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma.  NCT02285062

Lymphoma (2nd Line +) #LYM003:
For Study Participants with Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma (iNHL).   NCT02367040

Lymphoma #LYM004:
For Study Participants with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.   NCT01996865

Lymphoma #LYM005:
For Study Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.  NCT02998476

Ovarian Cancer Studies (Adjuvant or 1st Line) #OVA001:
For Study Participants with Previously Untreated Epithelial Ovarian Cancer.   NCT02718417

Prostate Cancer (1st Line) #PRO001:For Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.   NCT02111577

Renal Cancer (1st Line) #REN001:
For Study Participants with Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC).   NCT02853331

Select Advanced Cancers #P1-SAC001:For Study Participants with Select Advanced Cancers.   NCT02327078

Solid Tumors/Advanced #P1-STA001:
For Study Participants with Advanced Solid Tumors.   NCT02880371